Issue link: https://www.e-digitaleditions.com/i/1544305
30 April 2026 Inhalation Ellipta ® placebo blister (GlaxoSmithKline, London, United Kingdom), revealing the powder bed struc- ture inside. is enables calculation of powder bed statistics such as particle size distributions, powder packing densities and powder bed height. Furthermore, the technique can reveal fine micro- structural detail of real formulations. Figure 7 shows the powder bed within a Seretide ® 250 blister (GlaxoSmithKline, London, United Kingdom) [6], with the excipient lactose colored grey and the drug- phase rendered in color. is measurement was taken in situ, i.e., inside of the blister, and therefore did not require any sample preparation; moreover, the blister could be re-used for performance testing to link the pre-actuated and post-aerosolized microstructure. Despite these promising results shown by XCT for non-destructive analysis of inhalation formulations, all of the results shown above required sample prepa- ration by filling into Kapton-tube sample holders [12]. is filling process would certainly disturb the powder structure to some degree, and therefore, like all of the previously mentioned characterization techniques, XCT utilized in this manner would be considered destructive. True non-destructive analysis? Recent work has enabled viewing inside DPI blisters [20], notably without any need to open the blisters. erefore, in the true sense, it allows non- destructive measurement of the powder structuring within the blister. Figure 6 shows visualizations of a Trelegy ® Figure 2 Valuable insight into lactose monohydrate, a common excipient for DPI products, and model inhalation blends: (A, B) Difference in fine particle (orange) density and spatial location between sieved (A) and milled (B) grades; (C) Cracks within single lactose crystals; (D) Spatial distribution of particle sizes within a micronized lactose agglomerate. A B C D 100 µm 100 µm 10 µm 10 µm 0 5 10 µm

